Update on bisphosphonates and low-impact femoral fractures: Current evidence about an alendronate-fracture risk
Jennifer P. Schneider, MD, PhD
Geriatrics, 2009, in press
Several recent medical articles have described multiple cases of unusual low-impact subtrochanteric stress fractures or completed fractures of the femur in patients who have been on the bisphosphonate alendronate for several years for osteoporosis or osteopenia. Some patients have experienced such fractures in both femurs. The fractures are often preceded by pain in the affected thigh, may have a typical x-ray appearance, and many have delayed healing. It has been hypothesized that in some patients, long-term alendronate causes oversuppression of bone turnover, resulting in bones that are brittle despite improved bone density. In patients with atypical or low-impact fractures of the femoral shaft, consider the possible connection with alendronate use. Some bone specialists now recommend stopping alendronate in most patients after 5 years.
Schneider JP. Update on bisphosphonates and low-impact femoral fractures: Current evidence about an alendronate-fracture risk. Geriatrics. 2009;64(1):xx-xx.
Key words: alendronate, atypical fracture, femoral shaft, low-impact fracture, oversuppression, subtrochanteric,
Drugs discussed: alendronate, ibandronate, pamidronate, risedronate, teriparatide, zoledronic acid
Dr. Schneider practices Internal Medicine and Pain Management in
Disclosure: The author discloses that she has a personal interest in understanding the possible causative role of alendronate and atypical femoral fractures, as she was the patient in the 2006 Geriatrics case report. She has no financial interests in any pharmaceutical product used to treat osteoporosis.
A 66-year old, previously healthy woman developed a spontaneous stress fracture of her right foot, which eventually healed. Nine months later she took a step in her bedroom and collapsed to the floor. An X-ray revealed a nontraumatic fracture of her right femur. She underwent surgery with placement of an intramedullary rod. Her physician told her she had most likely had a stress fracture which became a completed fracture. A bone scan done shortly after her surgery revealed a stress fracture of her left femur. Some months later she underwent prophylactic rodding of the left femur. The patient had been on alendronate for 7 years.
A 65-year woman stepped visiting in
A 59 year old woman took a step, her right leg gave out, and she fell to the ground as she heard her leg break. Her femur was fractured. The orthopedic surgeon on call told her “We don’t usually see this type of fracture without trauma.” For the preceding year she’d experienced pain in her right thigh, which was severe enough to cause limping. An x-ray had been negative, and her primary care doctor thought she had fibromyalgia. She had been on alendronate for over 5 years.
These unpublished case reports, and several other similar ones, were sent to the author following publication of a 2006 report in Geriatrics of a 59-year old previously healthy woman who while riding on a subway train, suffered a comminuted spiral fracture of the right femur when the train jolted. (Figure 1, page xx). 1 The patient had been experiencing pain in her right thigh for 3 months. A bone scan 1 week before the fracture showed a stress fracture of the right femur. The patient had been taking alendronate, 70 mg/week for approximately 7 years for osteopenia, as well as calcium plus hormone replacement therapy. Despite prolonged use of an electrical bone stimulator, and cessation of alendronate use, the fracture did not unite. After 9 months, the patient had a second surgical procedure to replace the original rod with a larger one. After a delay, the bone finally united. The author suggested a possible causal relationship between long-term alendronate and the femoral fracture.
Fragility fractures of the proximal femur are rare. However, in the past 3 years, multiple additional cases like those above have been published and the evidence continues to grow that in a small subpopulation of patients, long-term alendronate use may be related to low-impact, nontraumatic, or “atypical” fractures of the femur, often with delayed healing. This paper reviews the older evidence for a connection between bisphosphonates and bone fragility, and summarizes recent reports and recommendations.
Femoral fractures and alendronate
Bisphosphonates are considered first-line treatment for postmenopausal osteoporosis. They are prescribed for millions of geriatric patients. Bisphosphonates—alendronate (Fosamax), risedronate (Actonel), ibandronate (Boniva), and zoledronic acid (Zometa, Reclast)—inhibit bone resorption by decreasing the activity of osteoclasts. Extensive studies have shown that therapy with bisphosphonates improves bone density and decreases fracture risk.2-6 When discontinued after 5 years, the physiologic effect of alendronate continues for at least 5 years, with no increase in morphometric vertebral fracture risk or in the risk of nonvertebral fractures compared with patients who continued to take alendronate for the full 10 years.7 This result is consistent with the fact that alendronate is incorporated into bone matrix and has a biological half-life of more than 10 years.
Bone turnover is a natural part of maintaining bone health. When bone turnover is inhibited by bisphosphonates, microdamage that occurs regularly in bone but is normally repaired might accumulate after long-term use. There have long been concerns about the long-term safety of bisphosphonates because of their potential to cause oversuppression of bone turnover.8-13 The first report suggestive of the clinical relevance of these hypothetical concerns was published in 2005 by Odvina et al14, describing 8 postmenopausal women and 1 man who sustained unusual nontraumatic nonspinal fractures while on alendronate therapy for 3-8 years. All 9 continued taking alendronate after the fracture. Six of the 9 patients had delayed or absent fracture healing for 3 months to 2 years during continued alendronate therapy. All 9 patients underwent iliac crest biopsy of trabecular bone. All the specimens showed markedly suppressed bone formation. The authors concluded that long-term alendronate therapy may result in severe suppression of bone turnover, and thus with increased susceptibility to nonspinal fractures along with delayed healing.
In 2007 a group from Singapore published a retrospective review of patients admitted with a low-energy subtrochanteric fracture (defined as one in the region of the femur which extended from the lesser trochanter to the junction of the proximal and middle third of the femoral shaft.) 15 Of 13 women identified,9 were on long-term alendronate therapy (mean 4.2 years (range 2.5-5)). Their average age was 67 years, versus 80 years in the non-alendronate group. Four of the 9 patients in the alendronate group reported that the fracture had occurred in the absence of a fall. Five patients reported experiencing prodromal pain in the fractured limb, starting 2-6 months before the injury; none of the patients in the non-alendronate group had prodromal symptoms. In 6 patients in the alendronate group, cortical hypertrophy was identified on the lateral side of the subtrochanteric region of the femur, and 3 of these also had cortical hypertrophy on the contralateral femur.
In 2008 a group from the Hospital
for Special Surgery, an orthopedic hospital in
The same group also reported on a retrospective review of patients with femoral shaft fractures (including the 15 in the prior report) admitted between January 2002 and March 2007.18 Seventy low-energy fractures were identified, in 59 females and 11 males, with an average age of 74.7 years. Osteoporosis was present in 44% of the 70 patients. Twenty-five patients (36%), all women, were being treated with alendronate, 84% for osteoporosis; none of the patients had used any other bisphosphonate. Of the 25, 19 (76%) had a specific pattern to the fracture – it was transverse, with a one-sided beak in an area of thickening of the cortex. This fracture pattern was seen in only 1 patient (2%) of patients not being treated with alendronate. The odds ratio for this pattern was 139.33 for alendronate users, and was 98% specific to identifying alendronate users. The patients with this pattern had been using alendronate for a mean of 6.9 years. The authors concluded that although they have not established a causal relationship, such fractures may result from propagation of a stress fracture whose repair is retarded by decreased osteoclast activity and impaired microdamage repair resulting from the prolonged use of alendronate. Minimal trauma is then required to produce a completed fracture.
Fragility or insufficiency fractures are a type of stress fracture that occurs in osteoporotic bone subjected to normal levels of stress. They typically occur in the vertebrae, hip, distal radius, and the proximal humerus following minimal or no trauma, but only rarely in the proximal femur.19 The subtrochanteric region of the femur is one of the strongest parts of the femur and it is unlikely to fracture in low low-energy trauma unless extreme osteoporosis is present.15 The reports of multiple cases of low-impact femoral fractures in patients who were taking alendronate for several years, a previously rare event, has therefore called for further study of the possible connection between alendronate and such fractures, as has been suggested by several authors.
is stored in the bone for many years and is reactivated as bone is turned over
and the drug re-enters the circulation.
Patients on long-term alendronate who
experienced completed fractures of the femur with minimal trauma continue to be
at risk of additional insufficiency fractures. In those in whom a stress fracture was
subsequently diagnosed in the contralateral femur,
prophylactic surgical rodding is typically suggested
in order to prevent a completed fracture. Some bone specialists treat such
patients with teriparatide (
Osteonecrosis of the jaw
The evolution of our understanding of the relationship between alendronate and femoral fractures parallels the growing understanding of the relationship between use of bisphosphonates and osteonecrosis of the jaw (ONJ), which may reflect a similar mechanism of bone injury. After numerous publications of multiple case reports, a population-based analysis of IV bisphosphonate therapy concluded that the hazard ratio of being diagnosed with inflammatory conditions or osteomyelitis of the jaw was 11.48 for recipients of IV bisphosphonates as compared with non-recipients.25 No randomized, controlled, double-blind studies have been done regarding bisphosphonates and ONJ, and they are unlikely to be done in the future. Nonetheless, the case reports and population studies have led to the creation of a new syndrome in the dental world, Bisphosphonate-associated Osteonecrosis of the Jaw (BON), and position papers on trying to prevent this disorder have been published by several organizations concerned with dental surgery.
Although most cases of ONJ have occurred in patients treated with IV bisphosphonates (pamidronate, zoledronic acid), the finding of some cases related to oral bisphosphonates resulted in the recent publication by the American Dental Association of “Dental management of patients receiving oral bisphosphonate therapy.26 This document suggests that “because there is no validated diagnostic technique currently available to determine if patients are at increased risk for developing BON, it may be prudent to proceed conservatively in some cases.” For example, if full-mouth tooth extract is needed, begin by extracting one tooth and see if the jaw heals. The Association of Oral and Maxillofacial Surgeons published guidelines in 2006 that state, “If systemic conditions permit, it has been proposed that discontinuation of oral bisphosphonates for a period of 3 months prior to and 3 months following elective invasive dental surgery may lower the risk of bisphosphonate-related ONJ.” 27 There are no actual data as yet to help determine the appropriate length of time the patient should be off the bisphosphonate, and this depends on the particular drug.
Nonetheless, the dental profession’s current guidelines are a model for prudent, patient-centered care in an environment where definitive high-grade studies are lacking but where there are reports of multiple, difficult-to-treat cases strongly suggestive of a bisphosphonate cause. There is already a published case report in the dental literature of a refractory case of ONJ that was successfully treated with teriparatide.28
Citing the 2006 report by Black et al about stopping or continuing alendronate after 5 years of treatment 7 the National Osteoporosis Foundation (NOF), in its Clinical Update Online of July 08, wrote, “Results suggest that for most women, taking a five-year “drug holiday” after being on alendronate (5-10 mg/day ) for five years does not increase fracture risk and might be advantageous. For women at high risk for vertebral fractures, continuing alendronate for a total of 10 years is a reasonable clinical option.” 29
In 2008 the NOF published a Clinician’s Guide to Prevention and Treatment of Osteoporosis. This guide introduced a new Fracture Risk Algorithm (FRAX) for calculating which men and women over 50 require pharmacologic treatment for osteoporosis.The report states that FRAX analyses generally confirm that it is cost-effective to treat individuals with a prior hip or vertebral fracture and those with a DEXA femoral neck –T score of -2.5 or worse. (p. 15).
The guide does not discuss the recommended duration of treatment with bisphosphonates. It does discuss the usefulness of biochemical markers of bone metabolism, saying, “Suppression of biochemical markers of bone turnover after 3-6 month of specific antiresorptive osteoporosis therapies, and biochemical marker increases after 1-3 months of specific anabolic therapies, have been predictive of greater BMD responses in studies evaluating large groups of patients. Because of the high degree of biological and analytical variability in measurement of biochemical markers, changes in individuals must be large in order to be clinically meaningful.”30
The North American Menopause Society (NAMS) , in their 2006 position statement on management of osteoporosis in post-menopausal women, says, “Current evidence does not support recommendations regarding the optimal duration of bisphosphonate therapy.” 31.
In the absence of definite
guidelines from NOF or
There may be a group of patients with low bone density who should not be treated with bisphosphonates. At present there is no way of predicting who these patients are. There is a need for research designed to identify those patients who are potentially at risk for adverse outcomes with bisphosphonates in general, or with alendronate in particular. These patients undoubtedly constitute a small percentage compared to those who benefit from bisphosphonates, but for those patients these fractures can be devastating events, to be prevented if at all possible.
Population research is also needed which compares the incidence of subtrochanteric fractures among people being treated with alendronate with the incidence among a group with comparable bone density who have not been treated with alendronate. This remains to be done. In September 2008 at a bone research meeting researchers reported a large Danish registry cohort analysis showing that alendronate use was indeed significantly associated with an increased risk of atypical subtrochanteric fractures.32 The alendronate group had an incidence of subtrochanteric fractures of 2.9/1,000 patient years, compared with only 1.6 among the controls. However, regular hip fractures were also significantly more common among the alendronate group, suggesting that that the alendronate-treated group had weaker bones than controls in the first place. Clearly, additional population studies are needed.
It is uncertain yet whether all bisphosphonates, have the potential risk of suppressing bone repair, or only alendronate. Alendronate was the first bisphosphonate available and still the most widely used. Its long biological half life might make it more likely than other bisphosphonates to cause problems in susceptible patients. Physicians need to be aware that patients on bisphosphonates who experience low-impact femoral fractures may require additional evaluation and treatment along with surgical fixation. This might include bone scans to detect other stress fractures, stopping alendronate therapy, and referral to specialists knowledgeable in treating these unusual cases.
1. Schneider JP. Should bisphosphonates be continued indefinitely? An unusual fracture in a healthy woman on long-term alendronate. Geriatrics 2006; 61(1):31-33.
2. Cummings SR, Black DM, Thompson DE et al. Effect of alendronate on risk of fracture in women with low bone density but without vertebral fractures: Results from the Fracture Intervention Trial. JAMA 1998; 280(24):2077-2082.
3. Pols HA, Felsenberg D, Hanley DA et al. Multinational, placebo-controlled, randomized trial of the effects of elendronate on bone density and fracture risk in postmenopausal women with low bone mass: Results of the FOSIT study. Fosamax International Trial Study Group. Osteoporos Int 1999; 9(5):461-8.
4. Tonino RP, Meunier PJ, Emkey R et al. Skeletal benefits of alendronate: 7-year treatment of postmenopausal osteoporotic women. Phase III Osteoporosis Treatment Study Group, J. Clin Endoc Metab 2000; 85(9):3109-15.
Black DM, Thompson DE Bauer DC, Ensrud
K, Musliner T, Hochberg MC, Nevitt
MC, Suryawanshi S, Cummings SR. Fracture risk
reduction with alendronate in women with
osteoporosis: The Fracture Intervention Trial FIT Research Group. J Clin Endocrinol
6. Orwoll E, Ettinger M, Weiss S, et al. Alendronate for the treatment of osteoporosis in men. N Eng J Med 2000; 343(9):604-610.7. Black DM, Schwartz AV, Ensrud KE, Cauley JA et al. Effects of continuing or stopping alendronate after 5 years of treatment: The Fracture Intervention Long-term extension (FLEX): A randomized trial. JAMA 2006; 296:2927-2938.
7. Mashiba T, Turner CH, Hirano T, ForwoodMR, Johnston CC, Burr DB. Effects of suppressed bone turnover by bisphosphonates on microdamage accumulation and biomechanical properties in clinically relevant skeletal sites in beagles. Bone 2001; 28(5)524-31.
8. Hirano T, Turner CH Forwood MR, Johnson CC Burr DB. Does suppression of bone turnover impair mechanical properties by allowing microdamage accumulation? Bone 2000:227(1)13-20.
9. Boivin G, Meunier PJ. Changes in bone remodeling rate influence the degree of mineralization of bone. Connect Tiss Res 2002; 43(2-3):535-7.
10. Akkus O, Polyakova-Akkus, Adar F, Schaffler MB.Aging of microstructural compartments in human compact bone. J Bone Miner Res 2003; 18(6):1012-9.
11. Ciarelli TE, Fyhrie DP, Parfitt AM. Effects of vertebral bone fragility and bone formation on the mineralization levels of cancellous bone from white females. Bone 2003; 32(3):311-15.
12. O’Brien FJ, Brennan O, Kennedy OD, and Lee TC. Microcracks in cortical bone: How do they affect bone biology? Current Osteoporosis Reports 2005; 3:39-45.
13. Odvina CV, Zerwekh JE, Rao DS et al. Severely suppressed bone turnover: A potential complication of alendronate therapy. J Clin Endocrinol Metab 2005; 90(3):1897-99.
15. Kwek EBK, Goh SK, Koh JSB, Png MI and Howe TS. An emerging pattern of subtrochanteric stress fractures: A long-term complication of alendronate therapy? Injury, Int J Care Injured. 2008;
16. Lenart BQ, Lorich CG and Lane JM. Atypical fractures of the femoral diaphysis in postmenopausal women taking alendronate. N Engl J Med 2008; 358(12):1304-1306.
18. Gibson MV. Evaluation and treatment of bone disease after fragility fracture. Geriatrics 2008 63(7):21-30.
19. McClung M, San Martin J, Miller PD, Civiteli R et al. Opposite bone remodeling effects of teriparatide and alendronate in increasing bone mass. Arch Int Med 2005; 1762-1768.
20. Differential effects of teriparatide on BMD after treatment with raloxifene or alendronate. J Bone Miner Res 2004; 19:745-751.
Miller PD, Delmas PD, Lindsay R,
22. Lenart BA, Lorich DG, and Lane JM. More on atypical fractures of the femoral diaphysis. Letter in NEJM 008:359(3):317-318.
23. Miller P. Personal communication 7/08.
24. Wilkinson GS, Kuo Y-F, Freeman JL, and Goodman JS. Intravenous bisphosphonate therapy and inflammatory conditions or surgery of the jaw: A population-based analysis. J Nat Cancer Inst 2007; 99:1016-24.
25. American Dental Association: Dental management of patients receiving oral bisphosphonate therapy: Report of the Council on Scientific Affairs.l July 1998. Accessed 9-6-08 at: http://www.ada.org/prof/resources/topics/topics_osteonecrosis_bisphosphonate_report.pdf.
26. American Association of Oral and Maxillofacial Surgeons. Position Paper on Bisphosphonate-Related Osteonecrosis of the Jaw. 2006. Accessed 9/12/08 at http://www.aaoms.org/docs/position_papers/osteonecrosis.pdf.
27. Harper RP. Resolution of bisophosphonate-associated osteonecrosis of the mandible: Possible application for intermittent low-dose parathyroid hormone [rhPTH(1-34)]. J Oral Maxillofac Surg 2007; 65:573-580.
28. CUOnline-July08-forweb.pdf, available at www.nof.org.
30. North American Menopause Society, 2006. Position Statement: Management of osteoporisis in postmenopausal women: 2006 position statement of the North American Menopause Society. Menopause: The Journal of the North American Menopause Society 13(3):340-367.
31. http//:medpagetoday.com/meetingCoverage/ASBMR/tb/10904, accessed 9/22/08)